More news >

In Brief

The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD).   19 July 2024

Mergers and Acquisitions

One to Watch Companies

A German biotech company developing immunotherapies aiming to prevent or reverse cancer resistance to checkpoint inhibition, chemotherapy and other targeted treatments.
A clinical-stage biotechnology company focused on transforming cardiometabolic diseases.
Aphaia Pharma is a clinical-stage biopharmaceutical company with headquarters in Switzerland, Canada and Puerto Rico.
Exsilio Therapeutics is developing genomic medicines that can be delivered in lipid nanoparticles to durably and safely treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions.
More Ones to Watch >


US biotech major Gilead Sciences has announced that chief medical officer (CMO) Merdad Parsey will leave the company early next year.   18 July 2024
US pharma major AbbVie has announced that Steve Hopkinson has been appointed as vice president and general manager, UK.   16 July 2024
Privately-held inflammatory disease specialist SFA Therapeutics has appointed James Kirwin as chief operating officer.   16 July 2024
Nucleome Therapeutics, a UK biotech using spatial genomics to discover precision medicines for complex diseases, has appointed Mark Bodmer as chief executive.   16 July 2024
More In The Boardroom >